



Investor Presentation
Strategic Review and Capital Raise
Neurotech International Limited (ASX: NTI) | 29 January 2019

Neurotech

Disclaimer

IMPORTANT INFORMATION

Purpose of presentation: This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech International Limited (ACN 610 205 402) (**Neurotech** or **Company**). It has been prepared for the sole purpose of providing general information on Neurotech and its business.

Not an offer or solicitation: This presentation is not investment advice nor an offer to subscribe for securities or otherwise invest in Neurotech, and it should not be relied upon to make any investment decision. Further, it does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of securities pursuant to this presentation in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful under applicable law, including the Securities Act of 1933 (USA), as amended (**US Securities Act**). Securities have not been registered under the US Securities Act or any US state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the US Securities Act and applicable state securities laws.

Not a prospectus: This presentation is not a prospectus, product disclosure statement or other investment disclosure document, and the level of disclosure in this presentation is less than such disclosure documents. It has not been lodged with any regulatory or supervisory body. This presentation does not purport to contain all of the information that a prospective investor may require to make an evaluation of Neurotech or its business activities and nothing in this presentation is, or is intended to be, a recommendation to invest in Neurotech. Neurotech does not purport to give financial or investment advice. Account has not been taken of the objectives, financial situation or needs of any recipient of this presentation.

Forward-looking statements: This presentation contains forward-looking statements which may be predictive in nature and incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets' or 'expects'. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that many of the events are outside Neurotech's control. The stated events may differ materially from results ultimately achieved. Accordingly, neither Neurotech nor any of its directors, employees, contractors or advisors make any warranty or assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur. Further, other than as required by law, Neurotech may not update or revise any forward-looking statement if events subsequently occur or information subsequently becomes available that affects the original forward-looking statement.

Disclaimer: Neither Neurotech nor its officers, employees, contractors or advisers make any warranty (express or implied) as to the accuracy, reliability, relevance or completeness of the material contained in this presentation. Nothing contained in this presentation is, or may be relied upon as a promise, representation or warranty, whether as to the past or the future. Neurotech excludes all warranties that can be excluded by law. Except for statutory liability which cannot be excluded, Neurotech, its officers, employees, contractors and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in this presentation and exclude all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.







Professional advice: Recipients of this presentation should consider seeking appropriate professional financial, taxation and legal advice in reviewing the presentation and all other information with respect to Neurotech and evaluating its business, financial performance and operations.

Proprietary information and copyright: This presentation and the information it contains is proprietary to Neurotech. Neurotech holds the copyright in this presentation. Except as permitted under the Copyright Act 1968 (Australia), this paper or any part thereof may not be reproduced without its written permission.

Overview

- Neurotech is focussed on the development & commercialisation of **neurological solutions that improve quality of life**
- **Our flagship Mente device and therapy is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated delta band brain activity**
- Following significantly positive results from a 2018 clinical trial, a review of our strategic direction has prompted a shift to leverage a proven technology to:
 - **Expand Mente's use beyond autism**, to target a broader market
 - **Drive affordability for consumers** by focussing on a per session subscription model
 - **Drive value proposition for clinics** by packaging otherwise specialist neurofeedback treatment, and creating a new recurring, clinic revenue stream
- This sits in line with **our vision of bringing clinical grade, wearable and portable neurotechnology into the home, making it affordable and accessible to those who need it**
- Neurotech is seeking to **raise up to A\$3.3 million** at 3 cps via a 1 for 1 renounceable rights issue to execute on the strategy and fund operations for the next 12 months. Each right will come with a 1 free attaching option, exercisable at 6 cps on or before 31 March 2021

Highly Experienced Board & Advisers

Board & Management		Peter O'Connor Chairman (Non-Exec) MA, Barrister-at Law	<ul style="list-style-type: none"> • Deep experience in global funds management, asset allocation & manager selection advisory • Held senior public company directorships (UK, Canada & Australia) • Non-executive director of Northern Star Resources (ASX:NST)
		Peter Griffiths Chief Executive Officer & Managing Director B.Sc. (Hons)	<ul style="list-style-type: none"> • 20 years of senior level leadership experience in software & data analytics with CA Technologies, IBM & Cognos • Experience in transitioning and scaling cloud software business • Responsible for investment & strategy across five business units at CA Technologies, driving leadership in enterprise & growth markets
		Dr David Cantor Non-Exec Director Ph.D	<ul style="list-style-type: none"> • Highly distinguished clinician, neuroscientist, program developer with career spanning over 40 years • CEO & Clinical Director of Mind & Motion Development of Georgia, a multidisciplinary treatment facility providing a range of diagnostic & treatment services to children & adults • CEO & Managing partner of BrainDx, a software company that develops functional brain analytic software
		Dr Neale Fong Non-Exec Director MBA, MBBS	<ul style="list-style-type: none"> • Registered medical practitioner with +35 years experience in a wide range of leadership roles in the private & public hospital system • Executive Chairman of Bethesda Health care, Chair of the WA Country Health Service, the WA Governments' Ministerial Council for Suicide Prevention & National President of the Australasian College of Health Service Management
		Simon Trevisan Non-Exec Director B.Ec, LLb (Hons), MBT	<ul style="list-style-type: none"> • 20+ years of experience in public & private investments, corporate finance & management of large public & private businesses • Managing Director of Tribis & Iris Residential • Director of Assetowl Ltd (ASX:AO1), Zeta Petroleum (ASX:ZTA) & BMG Resources (ASX:BMG)
Advisor		Dr Adrian Attard Trevisan Founder, Ph.D	<ul style="list-style-type: none"> • Neuroscientist, founder of AAT Research & key developer of Mente • PhD in Neuroscience (University of London), PhD in Human Physiology (Università degli Studi di Milano), Masters in Engineering & Audiological Sciences • Research Fellow at Bedfordshire Centre for Mental Health Research (BCMHR) in association with the University of Cambridge

“It’s pleasing to see the renewed focus and energy in the company. The strategy of enabling clinics with the Mente therapy and building on the unique values with artificial intelligence and software automation is where I believe Mente can really make a difference in the world.”

Dr Adrian Attard Trevisan, Founder

New Strategic Direction

New Model Strategic Highlights




Steady Recurring Revenue with Pathway to Significant Growth

- The new subscription model envisages a higher proportion of recurring revenue stream through the ongoing sale of therapy sessions to clinics
- Neurotech anticipates a reduction in the volatility of future earnings and an uptick in gross margins as the clinic base grows
- The therapy model greatly reduces the initial outlay required to get started with Mente and aligns with the medical consumables approach
- Over time and based on patient success and ongoing usage, the therapy model is more profitable and scalable through the expansion of therapy options



Significantly Broadened Market Beyond Autism

- Mente will be repositioned as a neurofeedback device that is able to address a range of behaviours (such as lack of engagement or focus) rather than concentrating solely on the condition of autism
- Importantly, there is no change in the hardware or therapy algorithms required – it is already independently proven to work, in a sample set of autistic children – the neuro-profile addressed by the therapy is common across a number of neurological conditions
- The approach materially extends the range of children that the technology is able to benefit and broadens our addressable market



Lower Adoption Barriers & Clinics are Aligned to Grow Revenue

- New model eliminates the high initial capital outlay from patients which provides a low resistance entry for Mente into the market
- Mente bridges the gap between specialist neurofeedback treatment and clinics who treat patients with a range of difficulties, including autism, ADHD, lack of sleep, etc.
- It does so by packaging proven therapy into sessions, which the clinics on-sell to their patients as part of a wider treatment plan
- Creates a simple, new and recurring revenue stream for clinics



Reduced Reliance on Distributors

- Majority of sales & marketing efforts will be directed to clinics and therapists
- Digital Marketing, eCommerce and Logistics services will be integrated to scale the model
- Regional Partners will be selected on their ability to scale and enable clinical networks
- Existing distribution network remains in place and will be transitioned overtime
- This brings the Company much closer to the customer, leverages digital best practices and the enables learning, refining and scaling of distribution practices to occur much more quickly

Our Vision

Bringing clinical grade, personalised neurotherapy into the home and school environment, making it affordable and accessible to those who need it.

Increasing availability
Improving outcomes



We achieve this through enabling and empowering clinicians and therapists to deliver tailored and proven neurofeedback therapy to their patients.

We are not limited to autism

Our Product is **mente**

Neurotech

{ relax
engage
focus }



Proven

The world's first home-based brain training therapy that is clinically proven to increase engagement & improve relaxation in autistic children with elevated delta band brain activity

Adaptive

Each Mente device analyses the individual's EEG & delivers personalised brain training in an audio therapy session where the child can continue with their typical morning routine

Complementary

Enables clinics, doctors & therapists to expand their practice into the home with a unique therapy

Minimally Disruptive

The child continues with their typical routine, supporting them in regular school learning & social activities

Science Supported by Positive Feedback

In 2018, a US independent, double-blinded clinical trial for autistic children found:

- **Significant reductions in abnormal levels of brainwaves**
- **Improvement in balance**
- **Positive effects and a reduction of autistic behaviours**
- **Parents indicating significant improvements in social skills and communication of their children**

Feedback from Italy, Germany and Turkey on Mente's efficacy is **highly aligned** with these findings, with parents pointing to:

- **Improved communication skills**
- **Improved behaviour**
- **Longer attention span**
- **Longer learning times**
- **Enhanced creativity**



"The improvements we have noticed are a better approach with his schoolmates... that has been seen by his teacher too."

Cristina, 8 y.o. Manuel's parent, Italy. Oct 2017

"My hopes were boosted when I heard his first word – "father". I will continue to use Mente Autism – within a short time my son has benefited a lot from the therapy."

Sadiye, 4.5 y.o. Samet's mother, Turkey. Aug 2018

"After 10 days of use, Kivanç was calmer and more open to receiving instructions..."

Special Education Teacher of 7 y.o. Kivanç, Turkey. Aug 2018

"We heard him speak his first words – mummy, daddy, come."

Parents of 7 y.o. boy, Turkey. Aug 2018



"... he started to draw as a means of recreation and with greater attention to descriptive detail that he never showed before..."

- Fabio & Cristina, 11 y.o. Samuel's parents, Italy. Oct 2017


"Since he started using Mente Autism, Mert is talking a lot more, his reactions to conversations have got better and his behaviour in kindergarten has improved."

Sendogan Demirtas, 5 y.o. Mert's parent, Germany. Aug 2017

Market Opportunity

Neurotech continues to be positioned between two growing trends of interest in neurotechnology & technology-enabled home care...

Estimated 2022 Market Sizes



Notes:

1. The Market for Neurotechnology: 2018 – 2022 – A market research report from Neurotech Reports.
2. Global Neurofeedback System Market Analysis 2012-2017 & Forecast 2018-2023.
3. Home Care Technology: 2018 – 2025. Grand View Research.
4. Autism prevalence ranges from 1 in 59 ([Centres for Disease Control](#)) to 1 in 160 ([World Health Organisation](#)).
5. ADHD prevalence occurs at a rate of 1 in 20 ([American Journal of Psychiatry 2007; 164:942–948](#)), noting that ADHD affects an estimated 30 – 60% of children with autism ([Autism Speaks](#)).

... & our addressable market is much broader than autism

- While the 2018 clinical study focussed on children with autism, its findings & the **existing** Mente technology are applicable to children who exhibit similar behavioural traits, such as lack of attention, focus & engagement
- ... **significantly broadening our potential market**
- Prevalence rates for autism & ADHD in children in the UK, US & Australia are shown below to illustrate:

Children who have trouble learning, focussing, being engaged, sleeping, relaxing...



Target Buyer

The market entry strategy will funnel from a targeted but sufficiently broad marketing campaign that focuses on clinics and therapists involved with early learning difficulties, playing into the behavioural traits (lack of attention, engagement) that Mente is seeking to modulate.

- The new business model has a much stronger focus on **clinicians and therapists** as Neurotech's target customer
- These clinicians:
 - Are in charge of delivering a package of patient care and determining appropriate treatment in deploying Mente
 - Form the primary (and trusted) channel to the parents and children
- Neurotech considers clinics which form **touch points to children and young adults with early learning difficulties as high priority**. These include the following clinic types:
 - Psychiatry
 - Neurology and Rehabilitation
 - General Care
 - Learning Disabilities
 - Mental Health
 - Occupational Therapy

An indication of the clinicians who could be targeted are shown below:

Practicing Clinicians and Therapists	United States	United Kingdom	Netherlands	Australia	
Population (2017)	326 million	66 million	17 million	25 million	
Psychiatrists	139,700	11,914	3,899	3,236	Higher priority
Psychologists	166,600	39,000	2,000	28,972	
Neurologists	16,366	1,755	1,241	539	
Occupational Therapists ¹	130,400	1,478	2,713	3,586	
Total Clinicians ex. Occupational Therapists	322,666	52,669	7,140	32,747	

1: Would seek to target those working with children with learning difficulties, and this could reduce the numbers.

The new model has been developed with input from clinical leaders and distributors in the US, UK, Netherlands, Italy, Greece and South Africa. Outreach with an initial group of UK clinics is under way, and to the extent possible, existing Mente distributors will be transitioned to the new subscription model over 2019.

Scale and Accelerate from Early Usage Success

Mente Active Users



“The interest in Mente has been incredible and global following our publication of our clinical trial.

We receive comments and notes from physicians throughout the world asking about obtaining Mente for their patients. There is a special interest in the United States and Canada with both doctors and clinics hoping that Mente will be available soon.

As such I hope that you might be able to introduce it into these markets so that physicians might be able to help so many patients and their families that are in need.


It appears to me that the technology is well suited for non-autism syndromes such as acute brain injury and a variety of neurological disorders. There is excitement to study its effectiveness and contribution to the diagnosis and treatment of brain functional disturbances in general”.

Professor Frederick R Carrick

Roland Blaauw Professor of Neurology & Senior Research Fellow BCMHR in association with University of Cambridge

New Subscription Model & Clinic Approach

... based on intensive internal review and external feedback



Benefits To Clinics

- New, recurring revenue stream – creating aligned channel partner
- Expands revenue & reach beyond physical clinic – creating leverage
- Low risk start up – with potential to recover outlay within a few months
- Easy to administer & access to own client info
- Fits into existing & well understood medical consumable models
- Online training & support provided by Neurotech

Benefits To Parents & Children

- Access clinical grade, proven, neurofeedback therapy from the home
- Supplements clinic's existing treatment plans
- Clinic provides an additional point of support & follow-up

Subscription Model – Example Pricing For Clinics

Starter Packs

- Includes headbands and an embedded requirement for clinics and clinicians to be trained and certified
- Designed to cover the cost of headband (€300) and a portion of loaded costs – acts as a marginal loss lead to therapy only subscription
- The Starter Patient Packs are currently designed for 9 - 12 weeks of therapy (average of 5 sessions per week)
- Includes a 30 day return guarantee

<p>€499</p> <p>Patient Pack</p> <p>1 Headband 45 Therapy Sessions On-Line Training & Certification</p> <p>€11.09/session 45 sessions per headband</p>	<p>€2,250</p> <p>Clinic 5 Pack</p> <p>5 Headbands 250 Therapy Sessions On-Line Training & Certification</p> <p>€9/session 50 sessions per headband</p>	<p>€4,500</p> <p>Clinic 10 Pack</p> <p>10 Headbands 600 Therapy Sessions On-Line Training & Certification</p> <p>€7.50/session 60 sessions per headband</p>
---	--	---

Therapy Only

- Headbands have already been acquired by clinic, and only top-up therapy sessions are required
- Costs relate to data analysis, storage and transfer, as well as ongoing clinic support
- Our model assumes that Clinics will be eligible for a new Headband after completing 500 therapy sessions

Pricing plans for USD, GBP, EUR and AUD to be built

<p>€299</p> <p>50 Therapy Top-Up</p> <p>€5.98/session</p>	<p>€899</p> <p>200 Therapy Top-Up</p> <p>Clinic Promotion</p> <p>€4.50/session</p>	<p>€1,699</p> <p>400 Therapy Top-Up</p> <p>Clinic Promotion Referral Priority</p> <p>€4.25/session</p>
<p>€499</p> <p>100 Therapy Top-Up</p> <p>€4.99/session</p>		

Our Strategic Horizons

HORIZON 1

Prove Go To Market (GTM) model in UK

0 - 6 months

GTM: SUBSCRIPTION

- Focus GTM on the Clinical Therapy & Clinic Business Model
- Reset Pricing to Subscription – Easy to Start
- Build in UK & Netherlands with goal **to target €100k annual recurring revenue (ARR) by Jun 2019** (100 patients)
- Embed technology partner for quantitative EEG & screening
- Work with existing distributors to progressively transition to new model

HORIZON 2

Expand geographies, expand treatment protocols

3 - 18 months

PLATFORM FOR GEOGRAPHIC & TREATMENT EXPANSION

- US market entry & European / Australia expansion
- Expand Mente home treatment protocols to address broader symptomatic behaviours such as lack of engagement, focus & inability to relax
- Implement machine learning for treatment guidance, efficacy & personalisation
- **€2,000k target ARR by Jun 2020** (1,500 patients)

HORIZON 3


Deliver better, multi-faceted product at lower cost

12 - 24 months

SENSOR HARDWARE & PARTNERSHIPS

- Reduce manufacturing costs from €300/unit to €280/unit by end of Jun 2020
- Improve physical product form
- Expand neurofeedback techniques beyond audio
- Increase home-based EEG resolution & simplicity
- Add synergistic offerings to the clinic to home platform to deliver multi-therapy offering
- **€3,000k target ARR by Dec 2020** (2,500 patients)

Projects & Milestones Underway



In Summary...

“The combination of neuro-assessment, neurofeedback and methods of brain entrainment which Mente delivers, uses powerful and state-of-the art techniques to facilitate clinical providers in the field of mental wellness to offer tools for their clients and make many of these tools conveniently utilised in the home, increasing access and helping to reduce costs to the consumer.

Whilst the recent clinical trial focused on children with ASD who exhibited a neurofunctional profile with specific bio markers, these same markers are also common in other conditions and it is reasonable to they can be used under the supervision of qualified clinicians to have a positive effect beyond autism.

The new business model of provider subscription and the potential to expand the scope of clinical treatment to the home presents an interesting opportunity which clinicians should consider as part of an overall practice approach.”

David S. Cantor, Ph.D.

CEO BrainDx, LLC, Neurotech Director and Chairman of the Scientific Advisory Board

Capital Raising Overview

- Neurotech is seeking to raise up to A\$3.3 million at 3 cps via a 1 for 1 renounceable rights issue to fund operations for the next 12 months
- Each right will come with a 1 free attaching option, exercisable at 6 cps on or before 31 March 2021
- The rights issue price represents a 35% discount to Neurotech's 1 month VWAP of 4.6 cents as at 25 January 2019
- The capital structure outcome, amount raised and use of funds under various uptake scenarios are shown on right

Potential Uptake	50%	75%	100%
Existing Shares	109,620,903	109,620,903	109,620,903
New Shares issued	54,810,452	82,215,677	109,620,903
Pro Forma Shares Outstanding	164,431,355	191,836,580	219,241,806
Existing Options ¹	10,894,390	10,894,390	10,894,390
New Options issued	54,810,452	82,215,677	109,620,903
Pro Forma Options Outstanding	65,704,842	93,110,067	120,515,293
Funds Raised (A\$)	1,644,314	2,466,470	3,288,627

Proposed Use of Funds ²	A\$	A\$	A\$
Software & Support	440,000	742,000	1,043,000
Production & Quality	164,000	258,000	351,000
Marketing	366,000	511,000	655,000
Research & Development	194,000	319,000	443,000
General Corporate & Working Capital	394,304	528,819	668,501
Capital Raising Costs ³	86,009	107,651	128,126
Total Uses	1,644,314	2,466,470	3,288,627

Notes:


- Options exercisable at \$0.20, with an expiration date of 30-Nov-2020.
- EUR denominated costs have been converted at EUR / AUD rate of 0.63.
- Excluding the costs of placing shortfalls, if any.

Capital Raising Indicative Timetable

Item	Indicative Date
Announcement of Offer and lodgement of Offer Documents with ASIC and ASX	Tuesday, 29 Jan
Shares quoted on a “ex-rights” basis and rights trading commences	Friday, 1 February
Record Date to determine entitlements (5pm, WST)	Monday, 4 February
Offer opens	Wednesday, 6 February
Rights trading ends	Wednesday, 13 February
New securities quoted on a deferred settlement basis	Thursday, 14 February
Offer closes (5pm, WST)	Wednesday, 20 February
Issue date	Monday, 25 February
Ordinary trading of new securities commences	Tuesday, 26 February

Our Journey

We have spent the last five years refining & validating Mente.



In the near term, we are focussed on:

- Leveraging positive validation of the Mente technology
- Broadening the market so that Mente is more accessible
- Placing Mente in the hands of clinicians as the key channel
- Adopting a subscription model to lower barriers & rapid testing of this model
- Continuous improvement of our algorithms through data capture & machine learning
- Making the device transaction simple & effortless

Historical distribution channels have been too far removed from the customer

The Science Behind Mente

Personalised & tailored therapy...


- Recognising that each person is unique & every day is different, Mente takes the individual's unique brainwave patterns in real time to produce auditory stimulation at specific frequencies to promote positive cognitive & behavioural outcomes

with broad application...

- Auditory feedback is delivered through binaural beats, training the brain to a desired brainwave that can lead to a different state of mind, becoming more relaxed, engaged or focused
- Outcomes of an independent, double blinded clinical trial in the United States in 2018 showed significant positive changes post a 12 week therapy regime across brain activity, balance & behaviour in autistic children¹

... that is particularly well suited to children

- Unlike most neurofeedback training tools, Mente facilitates adjustments of ongoing background brain activity **without** perceived attention or engagement from the user
- Ideal for children with difficulty paying attention for extended periods



Notes:

- The Treatment of Autism Spectrum Disorder with Auditory Neurofeedback: A Randomised Placebo Controlled Trial using the Mente Autism Device. Frontiers of Neurology, July 2018, Volume 9, Article 537.

Applied Clinical Research leads R&D

- Mente has successfully obtained its clinical validation against placebo units as part of the US Clinical Trial, **providing the scientific foundation to enable the commercial rollout** to clinics in the near term
- We envisage further discussions with clinical and university research partners to work through updated study protocols designed for big data collection and analysis environment
- We will enable systematic data collection from our digital platform, which will significantly broaden participant diversity and remove barriers due to enrolment and ongoing participation (e.g. physical disabilities or distance from centres)
- We will encourage clinicians to collaborate with us in collecting meta and classification data for each user and therapy paths - **enhancing personalised therapies with real world evidence**

**Completed
(2018)**

US Clinical Trial

Completed

Statistical Endpoints
Achieved

Clinical Validation
of Mente Autism

We bring the trial to the patient, rather than the other way round

Future State

Big Data Collection
(with clinicians and academic partners)

Systematic High Frequency
Data Collection & Analysis

Real World Evidence
of Mente's Impact

Existing Distributors

- In the 0 – 6 month horizon, our focus will be on enabling and supporting clinical practices and building referral networks directly, such that we learn and improve the system
- Over the 3 – 18 month horizon, we anticipate selected regional partners will operate virtual clinics to provide local support and scale services to clinics who do not want to administer Mente directly
- Existing Mente distributors will remain engaged through 2019 and will be transitioned to the new subscription / regional partner model as appropriate



Key Risks

Category	Risk	Mitigant
Business Model Risk	Mente system does not scale	The new subscription business model effectively reduces a large one-off cost to a pay-as-you-use system, thus, making the device more affordable & scalable to a larger demographic.
	Slow adoption of the Mente device	Neurotech has three marketing channels which include direct sales, distributors & digital marketing to aid with adoption. Neurotech is currently considering a fourth channel utilising endorsements from a champion or leading practitioner through the referral system.
Company Risk	Cyber liability, particularly for network & cloud-based Mente, in the event of breach of medical data or an attack that renders the technology inoperable	Network & Cloud services are provided by Microsoft Azure, one of the leading & most secure data platforms available. All data is encrypted at rest & in transit utilising the latest levels of encryption & security. In addition, patient data is kept separate from customer data, is pseudo-anonymised; & even in the event of a breach, no patients can be identified from the data. Backups are regularly made & tested.
	Consistent/ongoing usage not achieved in target group	Neurotech's new subscription model with opportunity for recurring revenue to the clinic incentivises clinicians & therapists to act as a channel partner, ensuring high utility of the device.
	Public Relations Issues / Backlash	Active marketing & public relations as part of the go-to-market strategy to proactively & rapidly address & respond to issues.
	Quality & robustness	Manufacturing agreement entered in January 2016 contains strict manufacturing quality controls based on international standards (ISO 13485) for the design & manufacturing of medical devices.
Regulatory Risk	Regulatory barriers / rejections	Mente's new positioning shifts to target wider behavioural traits in children & improving their wellbeing. This should significantly lower regulatory barriers in the target countries of operation.

Refer to the Offer Document for a comprehensive list of potential risks.

Contact Details



Company

Peter Griffiths, Chief Executive Officer
peter.griffiths@mentetech.com

Neurotech International Ltd
Level 14, 225 St Georges Terrace
Perth Western Australia 6000



Investor / Media Relations

Matthew Wright
matt@nwrcommunications.com.au

NWR Communications
Level 6, 350 Collins St
Melbourne Victoria 3000

Neurotech

www.neurotechinternational.com

www.mentetech.com